The Recursive operates three offerings that support founders, investors and technology companies across the European and Gulf ...

Recursion Pharmaceuticals (RXRX) is back in focus as investors weigh fresh updates on its AI-driven drug discovery platform, along with progress in key clinical assets REC-1245 and REC-4881 and ...

Recursive self-improvement AI now has a co-evolving evaluator: a Cambridge and NVIDIA preprint introduces the Red Queen Gödel ...

Microsoft's Eric Horvitz warns of a narrowing window to understand AI systems ...

Ben Taylor, CFO of Recursion, here with us. Thanks so much for joining us. Sure. Great. And first of all, thanks for having us here, Tommie. This is always a terrific conference and great to be here.

Recursion Pharmaceuticals combines artificial intelligence, automation, and biotechnology research across multiple ...

undefined quarterly & annual earnings - Track stocks financial health, Earnings performance, key metrics like revenue, net profit, and growth trends. Compare stock's quarter on quarter metrics such as ...

Abstract: Benchmark datasets normally have relatively conserved relationships and low fraction of outliers, indicated from higher determination coefficient (R2) and ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and ...

Integrating humanities into AI development is vital because societal impact is shaped by those who understand meaning, not just builders.